Clinical Trials Browser

Phase 2 × EGFR Positive Non-small Cell Lung Cancer × Clear all

NCT07322783 2026-01-07

Osimertinib Combined With Savolitinib in the Treatment of NSCLC With Low Copy Number MET Amplification

Phase 2 Recruiting

EGFR Positive Non-small Cell Lung Cancer

NCT03126799 2022-04-06

AvaTa

Phase 2 Unknown

EGFR Positive Non-small Cell Lung Cancer

NCT03382795 2021-07-15

Retreatment With Epidermal Growth Factor Receptor(EGFR) Tyrosine Kinase Inhibitor in EGFR Mutation Positive Patients

Phase 2 Unknown

EGFR Positive Non-small Cell Lung Cancer